Molecular Partners Announces New Clinical Data, Immunomodulation Platform Advances, and Virology Portfolio Strategy First-in-human data from ongoing phase 1 study of MP0310 (AMG 506) demonstrate encouraging biological activity, including successful localized tumor engagement and saturation Data from ongoing phase 1 COVID-19 study show that MP0420 (ensovibep) is well tolerated in first dose cohort Unique immunomodulation platforms advanced to readiness for candidate generation using CD-3 T cell engagers and pMHC binders Virology portfolio launched with focus on major global viral threats where unique DARPin® therapeutic profile could make major impact ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / December 17, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced multiple advances across clinical and preclinical programs, as well as an expansion of its corporate strategy to develop a portfolio of therapies targeting global viral threats. These advances will be detailed during a virtual R&D Day for investors and analysts starting at 9:00 a.m. ET on Thursday, December 17. (Registration link here)